• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Mclaughlin Kevin F exercised 7,000 shares at a strike of $2.76 and sold $279,860 worth of shares (7,000 units at $39.98) (SEC Form 4)

    5/9/25 4:05:21 PM ET
    $VCEL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $VCEL alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    MCLAUGHLIN KEVIN F

    (Last) (First) (Middle)
    C/O VERICEL CORPORATION
    64 SIDNEY STREET

    (Street)
    CAMBRIDGE MA 02139

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Vericel Corp [ VCEL ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/07/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/07/2025 M 7,000 A $2.76 22,100 D
    Common Stock 05/07/2025 S 7,000 D(1) $39.98 15,100 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $2.76 05/07/2025 M 7,000 (2) 05/04/2026 Common Stock 7,000 $0 7,000 D
    Explanation of Responses:
    1. The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2024.
    2. These options, representing the right to purchase a total of 15,000 shares, were originally granted on May 4, 2016, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company.
    /s/ Sean Flynn, as Attorney-in-Fact for Kevin McLaughlin 05/09/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VCEL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VCEL

    DatePrice TargetRatingAnalyst
    8/9/2024$57.00Buy
    Canaccord Genuity
    6/20/2024$55.00Buy
    TD Cowen
    1/25/2024$39.00 → $51.00Hold → Buy
    Truist
    8/8/2023$39.00Neutral → Buy
    BTIG Research
    11/10/2022Buy → Neutral
    BTIG Research
    11/9/2022Buy → Hold
    Truist
    10/14/2022$40.00Overweight
    Stephens
    2/25/2022$40.00 → $45.00Outperform
    SVB Leerink
    More analyst ratings

    $VCEL
    SEC Filings

    See more
    • SEC Form S-8 filed by Vericel Corporation

      S-8 - Vericel Corp (0000887359) (Filer)

      5/8/25 4:10:06 PM ET
      $VCEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Vericel Corporation

      S-8 - Vericel Corp (0000887359) (Filer)

      5/8/25 4:06:50 PM ET
      $VCEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Vericel Corporation

      10-Q - Vericel Corp (0000887359) (Filer)

      5/8/25 8:53:09 AM ET
      $VCEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VCEL
    Financials

    Live finance-specific insights

    See more
    • Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance

      Record First Quarter MACI Revenue of $46.3 Million and First Quarter Total Revenue of $52.6 Million Approximately 400 MACI Arthro Surgeons Trained to Date, with Year-to-Date Biopsy Growth Over 30% for Trained Surgeons Second Quarter Total Revenue and MACI Revenue Growth Expected to be in the Low- to Mid-20% Range Full-Year 2025 Revenue Guidance Reaffirmed and Profitability Guidance Raised Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business hi

      5/8/25 7:55:00 AM ET
      $VCEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025

      CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2025 financial results on Thursday, May 8, 2025. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Please visit the site at least 15 minutes prior to the scheduled start time to register and download the required audio software, if nec

      4/24/25 8:30:00 AM ET
      $VCEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vericel Reports Fourth Quarter and Full-Year 2024 Financial Results

      Full-Year Total Revenue Growth of 20% to $237.2 Million, with MACI Revenue Growth of 20% and Burn Care Revenue Growth of 22% Full-Year Adjusted EBITDA Growth of 58% to $53.4 Million Record Fourth Quarter Gross Margin of 78%, Adjusted EBITDA Margin of 40%, and Net Income of $19.8 Million Mid-Term Profitability Targets Increased to Gross Margin in the High-70% Range and Adjusted EBITDA Margin in the High-30% Range Strong MACI Arthro Key Launch Indicators, with Approximately 250 MACI Arthro Surgeons Trained to Date 2025 Financial Guidance with Total Revenue Growth of 20% to 23% Reaffirmed Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- V

      2/27/25 7:54:00 AM ET
      $VCEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VCEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mclaughlin Kevin F exercised 7,000 shares at a strike of $2.76 and sold $279,860 worth of shares (7,000 units at $39.98) (SEC Form 4)

      4 - Vericel Corp (0000887359) (Issuer)

      5/9/25 4:05:21 PM ET
      $VCEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Rubino Alan L converted options into 3,200 shares, increasing direct ownership by 7% to 45,994 units (SEC Form 4)

      4 - Vericel Corp (0000887359) (Issuer)

      5/2/25 4:06:58 PM ET
      $VCEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Wotton Paul K converted options into 3,200 shares, increasing direct ownership by 12% to 30,602 units (SEC Form 4)

      4 - Vericel Corp (0000887359) (Issuer)

      5/2/25 4:07:00 PM ET
      $VCEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VCEL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vericel Reports First Quarter 2025 Financial Results and Raises Full-Year Profitability Guidance

      Record First Quarter MACI Revenue of $46.3 Million and First Quarter Total Revenue of $52.6 Million Approximately 400 MACI Arthro Surgeons Trained to Date, with Year-to-Date Biopsy Growth Over 30% for Trained Surgeons Second Quarter Total Revenue and MACI Revenue Growth Expected to be in the Low- to Mid-20% Range Full-Year 2025 Revenue Guidance Reaffirmed and Profitability Guidance Raised Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business hi

      5/8/25 7:55:00 AM ET
      $VCEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vericel to Present at the Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025

      CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the Bank of America Securities 2025 Healthcare Conference at 12:20 p.m. ET (9:20 a.m. PT) on Wednesday, May 14, 2025. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com. About Vericel CorporationVericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resultin

      5/7/25 8:30:00 AM ET
      $VCEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vericel to Report First-Quarter 2025 Financial Results on May 8, 2025

      CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2025 financial results on Thursday, May 8, 2025. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights. The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Please visit the site at least 15 minutes prior to the scheduled start time to register and download the required audio software, if nec

      4/24/25 8:30:00 AM ET
      $VCEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VCEL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Vericel Corporation

      SC 13G/A - Vericel Corp (0000887359) (Subject)

      11/14/24 1:46:57 PM ET
      $VCEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vericel Corporation

      SC 13G/A - Vericel Corp (0000887359) (Subject)

      11/14/24 6:19:59 AM ET
      $VCEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vericel Corporation

      SC 13G/A - Vericel Corp (0000887359) (Subject)

      10/18/24 12:21:30 PM ET
      $VCEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VCEL
    Leadership Updates

    Live Leadership Updates

    See more
    • Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer

      CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, who served as Vericel's Head of Human Resources since September 2010. Ms. Mahoney joins Vericel with more than 20 years of experience across the life sciences and medical device sectors, most recently serving as Chief Human Resources Officer at Abiomed, a global medical device company that was acquired by Johnson & Johnson in December 2022. At Abiomed, Ms. Mahoney led all aspects of HR strategy and

      7/22/24 8:30:00 AM ET
      $VCEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • A-Alpha Bio Welcomes Heidi Hagen to Its Board of Directors

      Hagen, Former Chief Technical Officer of Sonoma Biotherapeutics, Joins as A-Alpha's First Independent Board Member SEATTLE, June 27, 2023 /PRNewswire-PRWeb/ -- A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions, announced the appointment of Heidi Hagen to their Board of Directors. Hagen will be A-Alpha Bio's first independent board member. Hagen has been a leader in the Biotechnology industry for 30 years. Over the course of her career, she has built an extensive track record in leading strategy and operations to progress innovative technologies from ideation to commercialization. Having been a core member of pharma companie

      6/27/23 9:00:00 AM ET
      $VCEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kytopen Appoints Paul K. Wotton, Ph.D. to Chair of Board of Directors

      New Independent Board Chair, Dr. Paul K. Wotton, brings 35 years of experience building private and public biopharmaceutical companies with significant business development expertise. Kytopen, an MIT-spin out and biotechnology company leading advancements in novel high-throughput cellular and genome engineering platforms, today announced the appointment of Paul K. Wotton, Ph.D. to Chair the Kytopen Board of Directors. Following the appointment of Dr. Wotton, the Board will comprise of five directors including Ann DeWitt, Adam Wieschhaus, Cullen Buie, and Paulo Garcia. Dr. Paul Wotton received his Ph.D. in Pharmaceutical Sciences from the University of Nottingham and is an experienced CEO,

      1/5/23 9:00:00 AM ET
      $VCEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $VCEL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on Vericel with a new price target

      Canaccord Genuity initiated coverage of Vericel with a rating of Buy and set a new price target of $57.00

      8/9/24 8:07:19 AM ET
      $VCEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TD Cowen initiated coverage on Vericel with a new price target

      TD Cowen initiated coverage of Vericel with a rating of Buy and set a new price target of $55.00

      6/20/24 7:39:49 AM ET
      $VCEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Vericel upgraded by Truist with a new price target

      Truist upgraded Vericel from Hold to Buy and set a new price target of $51.00 from $39.00 previously

      1/25/24 7:21:09 AM ET
      $VCEL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care